Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. - Wikidata - wikimedia - TriplyDB

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.

http://www.wikidata.org/entity/Q39612017

about

The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making Genetic polymorphisms of Bcl-2 promoter in cancer susceptibility and prognosis: a meta-analysis.BCL2 genotypes and prostate cancer survival.Personalized medicine and cancer.The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.Identification of thyroid carcinoma related genes with mRMR and shortest path approaches.A Polymorphism (rs1801018, Thr7Thr) of BCL2 is Associated with Papillary Thyroid Cancer in Korean Population.The BCL2 -938C>A Promoter Polymorphism Is Associated with Risk for and Time to Aseptic Loosening of Total Hip Arthroplasty.Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.Study of the regulatory promoter polymorphism (-938C>A) of B-cell lymphoma 2 gene in breast cancer patients of Mazandaran province in Northern Iran.Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis.Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity.Polymorphism in apoptotic BAX (-248G>A) gene but not in anti-apoptotic BCL2 (-938C>A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia.Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma.Role of polymorphisms in BCL-2 and BAX genes in modulating the risk of developing non-Hodgkin lymphoma.Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy.Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.Immunogenetics of prostate cancer: a still unexplored field of study.

P2860

Q27025062-565421E4-2EAC-412D-9438-25517ABDEDE6 Q33648842-BC39AE7B-972A-4D77-870B-07B50D799724 Q33708677-D49EBF9A-7D70-4E31-BEB0-213297D12002 Q34608577-3D34F531-BE93-44D9-A2A5-BBCA56761D4F Q35006917-51098BC7-A267-475F-9232-B6DB2E421742 Q35144091-5FCD6403-4882-498C-8C72-7E18C15B1B58 Q35214661-E820515E-C1C0-4813-B581-2D1D0CAB657D Q35924952-FCA19BFD-89AB-4533-AE41-D74849357241 Q36360770-FDA45A25-2C77-4764-B8FA-D575BDA43164 Q37735285-050B6936-F6E8-4971-A9BA-B114B4A63357 Q37741375-A07A5963-CAF3-43B0-A674-9600FB09A4D8 Q38833371-0AEC7BEF-2972-41E0-85FA-D854956F0CE0 Q39041693-B1A654EC-D84A-40E0-B1A7-4EF36CEC45D3 Q41053011-EB4EEB3E-BA60-4955-BB93-867A94B78911 Q41054527-AB30DEF3-B51E-414A-AAFC-8E4E1EA7DDAF Q41561910-5886DA90-856C-4493-B61E-4916ABE79195 Q44399860-9CFC2447-A464-4C01-AFCE-3FBCEBA09B36 Q44580350-213DE379-814B-4842-9FBF-70A74920EFD9 Q48835893-96512FD3-89B8-4CAF-BCC7-2E2E5A090220 Q49188143-B1D5ABB5-17D8-460C-B0F6-0125FC632203 Q50082109-44E80EFD-2ACF-435B-9392-F8CC5FFEFED0

P2860

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.

http://www.wikidata.org/entity/Q39612017

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Regulatory BCL2 promoter polym ...... ients with prostate carcinoma.

@en

Regulatory BCL2 promoter polymorphism

@nl

type

label

Regulatory BCL2 promoter polym ...... ients with prostate carcinoma.

@en

Regulatory BCL2 promoter polymorphism

@nl

prefLabel

Regulatory BCL2 promoter polym ...... ients with prostate carcinoma.

@en

Regulatory BCL2 promoter polymorphism

@nl

P1433

Q39612017-16B635B3-D7BD-4FF6-B5BA-D363CB6F5D47

P1476

Q39612017-2C21E2BD-E990-4694-B9FB-F9C72C9144BA

P2093

Q39612017-00897373-4C31-47AD-8854-185C32F2E592

Q39612017-1188273B-213E-4C78-A0D4-0BBCDF842BC7

Q39612017-3D2E4C19-0AB2-4120-827D-8ABB14C7E560

Q39612017-51B9E4BC-2F54-4211-9AF4-7F92FA3C767D

Q39612017-5FEB72CA-15A8-4505-B12D-C3357443EA9D

Q39612017-81D94482-DB22-4D25-9A32-4EEAC9C735E9

Q39612017-836D257C-AD59-4005-AFF0-E6BD595822D3

Q39612017-85DD5BB3-68F7-4265-AA6F-0EEAB597389E

Q39612017-8E9B536C-3F65-4BEA-AEDB-AC6E26D5DA53

Q39612017-93B2083D-5E36-4F60-AFFF-E7039FEA2867

P2860

Q39612017-0F0137E8-4AAF-43E7-94BF-B489EAB04F9C

Q39612017-154805B1-436B-4721-A87D-69FF440D6B57

Q39612017-22E3076D-8931-4D87-9CD5-9E0578F10BF1

Q39612017-3CBBBB4A-2ABC-43E6-B8F1-BA3A5D6C0341

Q39612017-3F59EC82-1A3D-46E2-A8AE-3E16427CF8EE

Q39612017-4C8178E8-5DBF-45CD-9CDB-A2749975AB48

Q39612017-4F849333-47A0-46AD-B690-4B47C2EBBBD8

Q39612017-547894B6-FC15-4F0F-9594-CC67D836587D

Q39612017-5DF91D56-D554-44DD-96AE-D7543B1B6922

Q39612017-60BF602D-976E-45BF-98F2-2F50EAE42CDF

P304

Q39612017-93FDF52D-EA92-4E61-80F1-A619B148632B

P31

Q39612017-C88B1C29-E877-41F5-B1C9-EECE4E1119A8

P356

Q39612017-80433B66-5EA3-4598-8A34-F04E4D3DD520

P433

Q39612017-8C0348BD-FE40-4D2F-9244-FCE990A8A746

P478

Q39612017-54A56A2E-F817-46AD-A76D-FC86881054F6

P577

Q39612017-B5C110B8-8C79-4406-AB40-066FF9355445

P5875

Q39612017-4F63BD61-A461-4024-8BD1-FA9FDBC70A57

P698

Q39612017-1B453F37-A416-43C6-A41E-19527C6A312F

P356

P1433

International Journal of Cancer

P1476

Regulatory BCL2 promoter polym ...... ients with prostate carcinoma.

@en

P2093

Alexander Schramm

http://www.w3.org/2001/XMLSchema#string

Andreas Eisenhardt

http://www.w3.org/2001/XMLSchema#string

Angelika Eggert

http://www.w3.org/2001/XMLSchema#string

Caroline F Hilburn

http://www.w3.org/2001/XMLSchema#string

Hagen S Bachmann

http://www.w3.org/2001/XMLSchema#string

Herbert Rübben

http://www.w3.org/2001/XMLSchema#string

Holger Nückel

http://www.w3.org/2001/XMLSchema#string

Johannes H Schulte

http://www.w3.org/2001/XMLSchema#string

Klaus J Schmitz

http://www.w3.org/2001/XMLSchema#string

Kurt Werner Schmid

http://www.w3.org/2001/XMLSchema#string

P2860

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

The Bcl2 family: regulators of the cellular life-or-death switch

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.

International trends and patterns of prostate cancer incidence and mortality.

A history of prostate cancer treatment

The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.

BCL2 family in DNA damage and cell cycle control.

A negative regulatory element in the bcl-2 5'-untranslated region inhibits expression from an upstream promoter.

Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer.

Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer.

P304

2390-2399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25904

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49729978

http://www.w3.org/2001/XMLSchema#string

P698

21207420

http://www.w3.org/2001/XMLSchema#string